<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00217724</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000446073</org_study_id>
    <secondary_id>OHSU-ONC-99037-L</secondary_id>
    <secondary_id>1252</secondary_id>
    <nct_id>NCT00217724</nct_id>
  </id_info>
  <brief_title>Glutamine in Preventing Myalgia and/or Arthralgia in Patients Who Are Receiving Paclitaxel For Cancer</brief_title>
  <official_title>A Double-blinded Pilot Study of Glutamine for the Prevention of Paclitaxel-Induced Myalgias and Arthralgias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the
      growth of cancer cells, either by killing the cells or by stopping them from dividing.
      Nutritional supplements, such as glutamine, may prevent side effects caused by chemotherapy.

      PURPOSE: This randomized clinical trial is studying glutamine to see how well it works
      compared to placebo in preventing myalgia and/or arthralgia in patients who are receiving
      paclitaxel for cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the efficacy of glutamine supplementation vs placebo, in terms of prevention of
           paclitaxel-induced myalgia and/or arthralgia, in patients with cancer.

      Secondary

        -  Compare the attenuation of myalgia and/or arthralgia in patients who experience myalgia
           and/or arthralgia treated with these regimens.

      OUTLINE: This is a randomized, double-blind, crossover, pilot study. Patients are randomized
      to 1 of 2 treatment arms.

        -  Arm I: Beginning on day 2 of course 1 of paclitaxel administration, patients receive
           oral glutamine three times daily for 4 days.

        -  Arm II: Beginning on day 2 of course 1 of paclitaxel administration, patients receive
           oral placebo three times daily for 4 days.

      Both arms crossover during course 2. In both arms, treatment continues in the absence of
      unacceptable toxicity.

      After completion of study treatment, patients are followed for 7-10 days.

      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Only able to accrue just 18 of the 40 target &amp; funds were limited.
  </why_stopped>
  <start_date>July 1999</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Response From Glutamine Preventing Paclitaxel Induced Myalgias or Arthralgias After 2 Courses of Chemotherapy</measure>
    <time_frame>2 courses of chemotherapy (6 weeks)</time_frame>
    <description>Complete Response (CR): Complete absence of myalgias or arthralgias Partial Response (PR): Myalgias and/or arthralgias occur but are attenuated in the cycle in which they receive active therapy by &gt; 50% Stable Disease (SD): Less than 25% change in incidence, duration, or severity of myalgias/arthralgias Progressive Disease (PD): Symptoms worsen by &gt;25% from baseline scores</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Attenuation of Myalgias or Arthralgias Not Receiving Glutamine as Measured by Pain Scale Diaries on Days 1 and 3 of Courses 1 and 2</measure>
    <time_frame>Duration of participation on study (up to one year)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Pain</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Glutamine Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beginning on day 2 of course 1 of paclitaxel administration, patients receive oral glutamine three times daily for 4 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Beginning on day 2 of course 1 of paclitaxel administration, patients receive oral placebo three times daily for 4 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>glutamine</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Glutamine Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria.

          -  Signed informed patient consent

          -  Adult patients (Age &gt; 18 years old) with a neoplastic disorder requiring paclitaxel as
             part of therapy, whether curative or palliative intent.

          -  Patients must have &gt; 2 additional planned courses of paclitaxel.

          -  Patients may be out-patient or in-patient at the time of enrollment.

          -  Patient must have had myalgias and/or arthralgias with the most recent course(s) of
             paclitaxel. Paclitaxel must be being administered over 3 hours or less for each
             infusion.

          -  Patients may have chronic pain but they must be able to differentiate it from either
             myalgias or arthralgias and be on a stable medication regimen for pain management.

          -  Eastern Cooperative Group (ECOG) Performance status score &lt; 3

          -  If consenting for the laboratory portion of the study the participant must have normal
             creatinine phosphokinase within 14 days of study entry.

          -  The patient, if sexually active, must be willing to agree to use an approved form of
             birth control.

        Exclusion criteria.

          -  The patient has received another investigational drug within the past 30 days.

          -  No myalgias or arthralgias in prior paclitaxel courses.

          -  The patient has uncontrolled (over the last 30 days), clinically significant
             confounding medical conditions such as rheumatoid disease, fibromyalgia, or chronic
             fatigue syndrome. Also if the patient has a viral infection, cold symptoms, fever (&gt;
             38 C -degrees celsius) or influenza.

          -  Patients with existing neuropathies or neurologic disorders which would prevent them
             from accurately assessing the onset or extent of myalgias and arthralgias.

          -  The patient has had significant medical intervention in the last 30 days

          -  The patient is pregnant or lactating.

          -  Patients who are unable to take oral medications or with medical conditions that might
             inhibit their ability to absorb protein from the gastrointestinal tract.

          -  Patients who are unwilling to abstain from additional protein supplements of any kind
             other than that obtained through &quot;normal&quot; dietary intake.

          -  Patients required to take nonsteroidal anti-inflammatory agents (NSAIDS), antioxidant
             vitamins, and unable or unwilling to abstain from them for 1 week prior to and during
             glutamine/placebo therapy.

          -  Patients with metabolic errors or abnormalities of protein metabolism.

          -  Patients with a history of blood urea nitrogen level &gt; 2 times normal with a normal
             serum creatinine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Bubalo, PharmD, BCPS, BCOP</last_name>
    <role>Study Chair</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>June 10, 2010</results_first_submitted>
  <results_first_submitted_qc>August 25, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 24, 2010</results_first_posted>
  <last_update_submitted>May 7, 2017</last_update_submitted>
  <last_update_submitted_qc>May 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Joseph Bubalo</investigator_full_name>
    <investigator_title>PharmD</investigator_title>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthralgia</mesh_term>
    <mesh_term>Myalgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from oncology clinics at OHSU.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Glutamine x 4 Days</title>
          <description>Oral glutamine 10g powder (dissolved in 8 oz orange juice) three times daily for 4 days starting day 2 of course 1 during Paclitaxel treatment.</description>
        </group>
        <group group_id="P2">
          <title>Oral Placebo x 4 Days</title>
          <description>Oral placebo 10g powder (dissolved in 8 oz orange juice) three times daily for 4 days starting day 2 of course 1 during Paclitaxel treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Course 1, (Glutamine/Placebo Arms)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Course 2, (Glutamine/Placebo Crossover)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes those randomized to Arms 1 and 2 in both course 1 and 2.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cancer Diagnosis</title>
          <description>Type of cancer diagnosis enrolled subject was receiving treatment for</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Breast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ovarian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Esophageal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uterine sarcoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Response From Glutamine Preventing Paclitaxel Induced Myalgias or Arthralgias After 2 Courses of Chemotherapy</title>
        <description>Complete Response (CR): Complete absence of myalgias or arthralgias Partial Response (PR): Myalgias and/or arthralgias occur but are attenuated in the cycle in which they receive active therapy by &gt; 50% Stable Disease (SD): Less than 25% change in incidence, duration, or severity of myalgias/arthralgias Progressive Disease (PD): Symptoms worsen by &gt;25% from baseline scores</description>
        <time_frame>2 courses of chemotherapy (6 weeks)</time_frame>
        <population>Fourteen of the 18 patients enrolled received both cycles of therapy and were thus evaluable for the primary endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Glutamine x 4 Days</title>
            <description>Oral glutamine 10g powder (dissolved in 8 oz orange juice) three times daily for 4 days.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo x 4 Days</title>
            <description>Oral placebo 10g powder (dissolved in 8 oz orange juice) three times daily for 4 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Response From Glutamine Preventing Paclitaxel Induced Myalgias or Arthralgias After 2 Courses of Chemotherapy</title>
          <description>Complete Response (CR): Complete absence of myalgias or arthralgias Partial Response (PR): Myalgias and/or arthralgias occur but are attenuated in the cycle in which they receive active therapy by &gt; 50% Stable Disease (SD): Less than 25% change in incidence, duration, or severity of myalgias/arthralgias Progressive Disease (PD): Symptoms worsen by &gt;25% from baseline scores</description>
          <population>Fourteen of the 18 patients enrolled received both cycles of therapy and were thus evaluable for the primary endpoint</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease (SD)/Progressive Disease (PD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Attenuation of Myalgias or Arthralgias Not Receiving Glutamine as Measured by Pain Scale Diaries on Days 1 and 3 of Courses 1 and 2</title>
        <time_frame>Duration of participation on study (up to one year)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Glutamine x 4 Days</title>
            <description>Oral glutamine 10g powder (dissolved in 8 oz orange juice) three times daily for 4 days.</description>
          </group>
          <group group_id="O2">
            <title>Oral Placebo x 4 Days</title>
            <description>Oral placebo 10g powder (dissolved in 8 oz orange juice) three times daily for 4 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Attenuation of Myalgias or Arthralgias Not Receiving Glutamine as Measured by Pain Scale Diaries on Days 1 and 3 of Courses 1 and 2</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected over the life of the study (3/2002-2/2007).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oral Glutamine x 4 Days</title>
          <description>Oral glutamine 10g powder (dissolved in 8 oz orange juice) three times daily for 4 days.</description>
        </group>
        <group group_id="E2">
          <title>Oral Placebo x 4 Days</title>
          <description>Oral placebo 10g powder (dissolved in 8 oz orange juice) three times daily for 4 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We were able to only accrue 18 of the 40 patient target. This, plus confounded results and limited funds, the remaining research funds were returned to the sponsor and no evaluation of serum or dietary glutamine levels was done.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Joseph Bublao</name_or_title>
      <organization>OHSU Knight Cancer Institute</organization>
      <phone>503-494-1054</phone>
      <email>bubaloj@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

